Inhibrx Biosciences, Inc.
INBX
$14.00
$0.000.00%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -14.21% | -42.49% | |||
| Gross Profit | 14.47% | 42.41% | |||
| SG&A Expenses | -750.30% | -91.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -138.53% | -70.93% | |||
| Operating Income | 138.75% | 70.92% | |||
| Income Before Tax | -9.12% | -102.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.12% | -102.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.12% | -102.36% | |||
| EBIT | 138.75% | 70.92% | |||
| EBITDA | 140.88% | 71.30% | |||
| EPS Basic | -9.12% | -102.23% | |||
| Normalized Basic EPS | 146.04% | 74.64% | |||
| EPS Diluted | -9.02% | -102.26% | |||
| Normalized Diluted EPS | 146.04% | 74.32% | |||
| Average Basic Shares Outstanding | 0.00% | 5.81% | |||
| Average Diluted Shares Outstanding | 0.00% | 4.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
